The global vagus nerve stimulators market is estimated to be valued at USD 667.4 Mn in 2025 and is expected to exhibit a CAGR of 9.9% during the forecast period (2025-2032). The vagus nerve is the longest cranial nerve that interacts with several organs of the body including the heart. Vagus nerve stimulation or VNS involves delivering electrical pulses to the vagus nerve using an implantable medical device called a vagus nerve stimulator. This therapy relies on the principle that stimulating the vagus nerve can help regulate abnormal brain activity and seizure control. Vagus nerve stimulators are used as an adjunctive therapy for reducing the frequency and severity of seizures in patients with epilepsy whose conditions are not fully controlled by medications. The therapeutic potential of VNS is being explored for treating other neurological and psychiatric disorders such as depression, Alzheimer's disease, and migraine too.
Market Dynamics:
The global vagus nerve stimulators market is driven by the rising prevalence of epilepsy and other neurological disorders, growing awareness and acceptance of VNS therapy, and favorable reimbursement policies. However, high costs associated with VNS devices and surgeries coupled with adverse effects and complications associated with stimulation of the vagus nerve act as key restraints for the market growth. Development of innovative stimulation devices with improved features and expanding therapeutic applications of VNS present high-impact rendering opportunities. Stakeholders are investing in research trials to evaluate the efficacy of VNS in conditions such as treatment-resistant depression, rheumatoid arthritis, and heart failure.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook